Formpipe Life Science Limited - Limited company accounts 18.2

Formpipe Life Science Limited - Limited company accounts 18.2


IRIS Accounts Production v18.2.0.360 05797675 director 1.1.17 31.12.17 31.12.17 false true true false false false true true true true true true true true true true true true true true true true false false false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure057976752016-12-31057976752017-12-31057976752017-01-012017-12-31057976752015-12-31057976752016-01-012016-12-31057976752016-12-3105797675ns14:PoundSterling2017-01-012017-12-3105797675ns10:Director12017-01-012017-12-3105797675ns10:PrivateLimitedCompanyLtd2017-01-012017-12-3105797675ns10:FRS1012017-01-012017-12-3105797675ns10:Audited2017-01-012017-12-3105797675ns10:LargeMedium-sizedCompaniesRegimeForDirectorsReport2017-01-012017-12-3105797675ns10:LargeMedium-sizedCompaniesRegimeForAccounts2017-01-012017-12-3105797675ns10:FullAccounts2017-01-012017-12-310579767512017-01-012017-12-310579767512017-01-012017-12-3105797675ns10:OrdinaryShareClass12017-01-012017-12-3105797675ns10:CompanySecretary12017-01-012017-12-3105797675ns10:RegisteredOffice2017-01-012017-12-3105797675ns5:CurrentFinancialInstruments2017-12-3105797675ns5:CurrentFinancialInstruments2016-12-3105797675ns5:ShareCapital2017-12-3105797675ns5:ShareCapital2016-12-3105797675ns5:SharePremium2017-12-3105797675ns5:SharePremium2016-12-3105797675ns5:RetainedEarningsAccumulatedLosses2017-12-3105797675ns5:RetainedEarningsAccumulatedLosses2016-12-3105797675ns5:ShareCapital2015-12-3105797675ns5:RetainedEarningsAccumulatedLosses2015-12-3105797675ns5:SharePremium2015-12-3105797675ns5:RetainedEarningsAccumulatedLosses2016-01-012016-12-3105797675ns5:RetainedEarningsAccumulatedLosses2017-01-012017-12-3105797675ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2017-01-012017-12-3105797675ns5:FurnitureFittings2017-01-012017-12-3105797675ns5:ComputerEquipment2017-01-012017-12-3105797675ns5:OwnedAssets2017-01-012017-12-3105797675ns5:OwnedAssets2016-01-012016-12-3105797675ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2016-12-3105797675ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2017-12-3105797675ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2016-12-3105797675ns5:FurnitureFittings2016-12-3105797675ns5:ComputerEquipment2016-12-3105797675ns5:FurnitureFittings2017-12-3105797675ns5:ComputerEquipment2017-12-3105797675ns5:FurnitureFittings2016-12-3105797675ns5:ComputerEquipment2016-12-3105797675ns5:WithinOneYear2017-12-3105797675ns5:WithinOneYear2016-12-3105797675ns5:BetweenOneFiveYears2017-12-3105797675ns5:BetweenOneFiveYears2016-12-3105797675ns5:AllPeriods2017-12-3105797675ns5:AllPeriods2016-12-3105797675ns10:OrdinaryShareClass12017-12-3105797675ns5:RetainedEarningsAccumulatedLosses2016-12-3105797675ns5:SharePremium2016-12-31


REGISTERED NUMBER: 05797675












Report of the Director and

Financial Statements

for the Year Ended 31 December 2017

for

Formpipe Life Science Limited

Formpipe Life Science Limited (Registered number: 05797675)






Contents of the Financial Statements
for the year ended 31 December 2017




Page

Company Information 1

Report of the Director 2

Report of the Independent Auditors 3

Statement of Comprehensive Income 5

Balance Sheet 6

Statement of Changes in Equity 7

Notes to the Financial Statements 8


Formpipe Life Science Limited

Company Information
for the year ended 31 December 2017







DIRECTOR: C C Q Sundin





SECRETARY: C C Q Sundin





REGISTERED OFFICE: 13 Poplars Court
Lenton Lane
Nottingham
Nottinghamshire
NG7 2PW





REGISTERED NUMBER: 05797675





AUDITORS: Clayton & Brewill
Statutory Auditors and
Chartered Accountants
Cawley House
149-155 Canal Street
Nottingham
Nottinghamshire
NG1 7HR

Formpipe Life Science Limited (Registered number: 05797675)

Report of the Director
for the year ended 31 December 2017

The director presents his report with the financial statements of the company for the year ended 31 December 2017.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of software supply and
consultancy.

DIVIDENDS
No dividends will be distributed for the year ended 31 December 2017.

RESEARCH AND DEVELOPMENT
The company continues to invest in research and development activities.

DIRECTOR
C C Q Sundin held office during the whole of the period from 1 January 2017 to the date of this report.

STATEMENT OF DIRECTOR'S RESPONSIBILITIES
The director is responsible for preparing the Report of the Director and the financial statements in
accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law
the director has elected to prepare the financial statements in accordance with United Kingdom Generally
Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company
law the director must not approve the financial statements unless he is satisfied that they give a true and
fair view of the state of affairs of the company and of the profit or loss of the company for that period. In
preparing these financial statements, the director is required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-state whether applicable accounting standards have been followed, subject to any material departures
disclosed and explained in the financial statements;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that
the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and
explain the company's transactions and disclose with reasonable accuracy at any time the financial
position of the company and enable him to ensure that the financial statements comply with the
Companies Act 2006. He is also responsible for safeguarding the assets of the company and hence for
taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the director is aware, there is no relevant audit information (as defined by Section 418 of the
Companies Act 2006) of which the company's auditors are unaware, and he has taken all the steps that
he ought to have taken as a director in order to make himself aware of any relevant audit information
and to establish that the company's auditors are aware of that information.

AUDITORS
The auditors, Clayton & Brewill, will be proposed for re-appointment at the forthcoming Annual General
Meeting.

ON BEHALF OF THE BOARD:





C C Q Sundin - Director


13 August 2018

Report of the Independent Auditors to the Members of
Formpipe Life Science Limited

Opinion
We have audited the financial statements of Formpipe Life Science Limited (the 'company') for the year
ended 31 December 2017 which comprise the Statement of Comprehensive Income, Balance Sheet,
Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant
accounting policies. The financial reporting framework that has been applied in their preparation is
applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 101
'Reduced Disclosure Framework' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31 December 2017 and of its loss
for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting
Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and
applicable law. Our responsibilities under those standards are further described in the Auditors'
responsibilities for the audit of the financial statements section of our report. We are independent of the
company in accordance with the ethical requirements that are relevant to our audit of the financial
statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical
responsibilities in accordance with these requirements. We believe that the audit evidence we have
obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require
us to report to you where:
- the director's use of the going concern basis of accounting in the preparation of the financial
statements is not appropriate; or
- the director has not disclosed in the financial statements any identified material uncertainties that may
cast significant doubt about the company's ability to continue to adopt the going concern basis of
accounting for a period of at least twelve months from the date when the financial statements are
authorised for issue.

Other information
The director is responsible for the other information. The other information comprises the information in
the Report of the Director, but does not include the financial statements and our Report of the Auditors
thereon.

Our opinion on the financial statements does not cover the other information and we do not express any
form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information
and, in doing so, consider whether the other information is materially inconsistent with the financial
statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If,
based on the work we have performed, we conclude that there is a material misstatement of this other
information, we are required to report that fact. We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Director for the financial year for which the financial
statements are prepared is consistent with the financial statements; and
- the Report of the Director has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the
course of the audit, we have not identified material misstatements in the Report of the Director.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us
to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been
received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of director's remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Report of the Independent Auditors to the Members of
Formpipe Life Science Limited


Responsibilities of director
As explained more fully in the Statement of Director's Responsibilities set out on page two, the director is
responsible for the preparation of the financial statements and for being satisfied that they give a true
and fair view, and for such internal control as the director determines necessary to enable the
preparation of financial statements that are free from material misstatement, whether due to fraud or
error.

In preparing the financial statements, the director is responsible for assessing the company's ability to
continue as a going concern, disclosing, as applicable, matters related to going concern and using the
going concern basis of accounting unless the director either intends to liquidate the company or to cease
operations, or has no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are
free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that
includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an
audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists.
Misstatements can arise from fraud or error and are considered material if, individually or in the
aggregate, they could reasonably be expected to influence the economic decisions of users taken on the
basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the
Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms
part of our Report of the Auditors.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16
of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's
members those matters we are required to state to them in a Report of the Auditors and for no other
purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone
other than the company and the company's members as a body, for our audit work, for this report, or for
the opinions we have formed.




Neil South BA FCA (Senior Statutory Auditor)
for and on behalf of Clayton & Brewill
Statutory Auditors and
Chartered Accountants
Cawley House
149-155 Canal Street
Nottingham
Nottinghamshire
NG1 7HR

13 August 2018

Formpipe Life Science Limited (Registered number: 05797675)

Statement of Comprehensive Income
for the year ended 31 December 2017

2017 2016
Notes £    £    £    £   

TURNOVER 736,235 620,068

Cost of sales 745,688 627,005
GROSS LOSS (9,453 ) (6,937 )

Distribution costs (14,361 ) 1,503
Administrative expenses 339,649 491,515
325,288 493,018
(334,741 ) (499,955 )

Other operating income 1,246 2,141
OPERATING LOSS (333,495 ) (497,814 )

Income from shares in group
undertakings

-

31,111
Interest receivable and similar income - 2,084
- 33,195
(333,495 ) (464,619 )
Amounts written off investments 4 - 31,111
(333,495 ) (495,730 )

Interest payable and similar expenses 5 35,752 28,083
LOSS BEFORE TAXATION 6 (369,247 ) (523,813 )

Tax on loss 8 - -
LOSS FOR THE FINANCIAL YEAR (369,247 ) (523,813 )

OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

(369,247

)

(523,813

)

Formpipe Life Science Limited (Registered number: 05797675)

Balance Sheet
31 December 2017

2017 2016
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 9 275,313 362,292
Tangible assets 10 14,139 27,660
289,452 389,952

CURRENT ASSETS
Stocks 11 - 180
Debtors 12 229,185 155,329
Cash at bank 81,522 53,769
310,707 209,278
CREDITORS
Amounts falling due within one year 13 1,593,465 1,223,289
NET CURRENT LIABILITIES (1,282,758 ) (1,014,011 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(993,306

)

(624,059

)

CAPITAL AND RESERVES
Called up share capital 15 13,143 13,143
Share premium 16 214,712 214,712
Retained earnings 16 (1,221,161 ) (851,914 )
SHAREHOLDERS' FUNDS (993,306 ) (624,059 )

The financial statements were approved by the director on 13 August 2018 and were signed by:





C C Q Sundin - Director


Formpipe Life Science Limited (Registered number: 05797675)

Statement of Changes in Equity
for the year ended 31 December 2017

Called up
share Retained Share Total
capital earnings premium equity
£    £    £    £   

Balance at 1 January 2016 13,143 (328,101 ) 214,712 (100,246 )

Changes in equity
Total comprehensive income - (523,813 ) - (523,813 )
Balance at 31 December 2016 13,143 (851,914 ) 214,712 (624,059 )

Changes in equity
Total comprehensive income - (369,247 ) - (369,247 )
Balance at 31 December 2017 13,143 (1,221,161 ) 214,712 (993,306 )

Formpipe Life Science Limited (Registered number: 05797675)

Notes to the Financial Statements
for the year ended 31 December 2017

1. STATUTORY INFORMATION

Formpipe Life Science Limited is a private company, limited by shares, registered in England and
Wales. The company's registered number and registered office can be found on the Company
Information page.

2. ACCOUNTING POLICIES

Basis of preparation
These financial statements have been prepared in accordance with Financial Reporting Standard
101 "Reduced Disclosure Framework" and the Companies Act 2006. The financial statements have
been prepared under the historical cost convention.

At 31 December 2017 the company has net current liabilities of £1,282,758 (2016: £1,014,011)
and net liabilities of £993,306 (2016: 624,059). The accounts have been prepared on a going
concern basis due to the continued financial support from the parent company.

The company has taken advantage of the following disclosure exemptions in preparing these
financial statements, as permitted by FRS 101 "Reduced Disclosure Framework":

the requirements of paragraphs 45(b) and 46 to 52 of IFRS 2 Share-based Payment;
the requirements of paragraphs 62, B64(d), B64(e), B64(g), B64(h), B64(j) to B64(m),
B64(n)(ii), B64(o)(ii), B64(p), B64(q)(ii), B66 and B67 of IFRS 3 Business Combinations;
the requirements of paragraph 33(c) of IFRS 5 Non Current Assets Held for Sale and
Discontinued Operations;
the requirements of IFRS 7 Financial Instruments: Disclosures;
the requirements of paragraphs 91 to 99 of IFRS 13 Fair Value Measurement;
the requirement in paragraph 38 of IAS 1 Presentation of Financial Statements to present
comparative information in respect of:
- paragraph 79(a)(iv) of IAS 1;
- paragraph 73(e) of IAS 16 Property, Plant and Equipment;
- paragraph 118(e) of IAS 38 Intangible Assets;
- paragraphs 76 and 79(d) of IAS 40 Investment Property; and
- paragraph 50 of IAS 41 Agriculture;
the requirements of paragraphs 10(d), 10)(f), 16, 38A, 38B, 38C, 38D, 40A, 40B, 40C, 40D
and 111 of IAS 1 Presentation of Financial Statements;
the requirements of paragraphs 134 to 136 of IAS 1 Presentation of Financial Statements;
the requirements of IAS 7 Statement of Cash Flows;
the requirements of paragraphs 30 and 31 of IAS 8 Accounting Policies, Changes in Accounting
Estimates and Errors;
the requirements of paragraphs 17 and 18A of IAS 24 Related Party Disclosures;
the requirements in IAS 24 Related Party Disclosures to disclose related party transactions
entered into between two or more members of a group;
the requirements of paragraphs 134(d) to 134(f) and 135(c) to 135(e) of IAS 36 Impairments
of Assets.

Formpipe Life Science Limited (Registered number: 05797675)

Notes to the Financial Statements - continued
for the year ended 31 December 2017

2. ACCOUNTING POLICIES - continued

Development costs
Development costs that are directly attributable to development and testing of identifiable and
unique software products under the companies control , are recognised as an intangible asset
when the following criteria are met.

- Its is technically feasible to complete the software so it is available for use.
- The company intends to complete the software and to use or sell it
- Conditions are present to use or sell the software
- It can be demonstrated how the software will generate probable future economic benefits
- Adequate terminological, financial, and other resources are available to complete development
and to use or sell the software
- The expenses directly attributable to the software, during its development can be reliably
measured.

Directly attributable expenses that are capitalised as part of the software development include staff
costs and an reasonable proportion of the indirect cost. Other development costs that do not meet
these criteria are charged as they arise.

Development costs for software recognised as an asset are depreciated over its estimated useful
life, which does not exceed five years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 25% on cost and Straight line over term of lease
Computer equipment - 33% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for
obsolete and slow moving items.

Taxation
Current taxes are based on the results shown in the financial statements and are calculated
according to local tax rules, using tax rates enacted or substantially enacted by the balance sheet
date.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange
ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at
the rate of exchange ruling at the date of transaction. Exchange differences are taken into account
in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to the profit or loss on a straight line basis over
the period of the lease.

Employee benefit costs
The company operates a defined contribution pension scheme. Contributions payable to the
company's pension scheme are charged to the income statement in the period to which they
relate.

3. EMPLOYEES AND DIRECTORS
2017 2016
£    £   
Wages and salaries 488,152 451,737
Social security costs 60,127 63,286
Other pension costs 37,231 37,780
585,510 552,803

Formpipe Life Science Limited (Registered number: 05797675)

Notes to the Financial Statements - continued
for the year ended 31 December 2017

3. EMPLOYEES AND DIRECTORS - continued

The average number of employees during the year was as follows:
2017 2016

Admin salaries 11 11

2017 2016
£    £   
Director's remuneration - -

4. AMOUNTS WRITTEN OFF INVESTMENTS
2017 2016
£    £   
Write off investments - 31,111

5. INTEREST PAYABLE AND SIMILAR EXPENSES
2017 2016
£    £   
Intercompany loan interest 35,752 25,814
Loan - 2,269
35,752 28,083

6. LOSS BEFORE TAXATION

The loss before taxation is stated after charging/(crediting):
2017 2016
£    £   
Cost of inventories recognised as expense 745,688 627,005
Other operating leases 23,161 22,404
Depreciation - owned assets 14,520 15,523
(Profit)/loss on disposal of fixed assets (14,361 ) 1,503
Development costs amortisation 55,199 44,411
Foreign exchange differences 12,543 103,996

7. AUDITORS' REMUNERATION
2017 2016
£    £   
Fees payable to the company's auditors for the audit of the
company's financial statements

7,408

8,850

8. TAXATION

Analysis of tax expense
No liability to UK corporation tax arose for the year ended 31 December 2017 nor for the year
ended 31 December 2016.

Formpipe Life Science Limited (Registered number: 05797675)

Notes to the Financial Statements - continued
for the year ended 31 December 2017

8. TAXATION - continued

Factors affecting the tax expense
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The
difference is explained below:

2017 2016
£    £   
Loss before income tax (369,247 ) (523,813 )
Loss multiplied by the standard rate of corporation tax in the UK
of 19.250% (2016 - 20%)

(71,080

)

(104,763

)

Effects of:
Losses carried forward 79,821 126,721
Development costs (16,478 ) (32,400 )
(Profit)/Loss on disposal of assets (2,764 ) 301
Depreciation charge in excess of capital allowances 10,501 10,141

Tax expense - -

A deferred tax asset of £101,180 (2016: £224,522) in respect of trading losses of £532,526
(2016: £1,181,693) has not been recognised due to uncertainty over future profits against which
to offset.
Previous tax losses of £635,690 were surrendered to a fellow UK subsidiary during the year.

9. INTANGIBLE FIXED ASSETS
Development
costs
£   
COST
At 1 January 2017 406,703
Additions 85,600
Disposals (129,088 )
At 31 December 2017 363,215
AMORTISATION
At 1 January 2017 44,411
Amortisation for year 55,199
Eliminated on disposal (11,708 )
At 31 December 2017 87,902
NET BOOK VALUE
At 31 December 2017 275,313
At 31 December 2016 362,292

Formpipe Life Science Limited (Registered number: 05797675)

Notes to the Financial Statements - continued
for the year ended 31 December 2017

10. TANGIBLE FIXED ASSETS
Fixtures
and Computer
fittings equipment Totals
£    £    £   
COST
At 1 January 2017 43,456 79,761 123,217
Additions - 999 999
At 31 December 2017 43,456 80,760 124,216
DEPRECIATION
At 1 January 2017 28,994 66,563 95,557
Charge for year 5,779 8,741 14,520
At 31 December 2017 34,773 75,304 110,077
NET BOOK VALUE
At 31 December 2017 8,683 5,456 14,139
At 31 December 2016 14,462 13,198 27,660

11. STOCKS
2017 2016
£    £   
Finished goods - 180

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2017 2016
£    £   
Trade debtors 147,642 69,747
Amounts owed by group undertakings 10,853 68,511
Prepayments and accrued income 70,690 17,071
229,185 155,329

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2017 2016
£    £   
Trade creditors 31,539 23,262
Amounts owed to group undertakings 1,433,019 1,116,447
Social security and other taxes 17,710 18,264
VAT 10,751 5,437
Other creditors 3,853 4,026
Accrued expenses 96,593 55,853
1,593,465 1,223,289

14. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2017 2016
£    £   
Within one year 22,404 22,404
Between one and five years 3,734 26,138
26,138 48,542

Formpipe Life Science Limited (Registered number: 05797675)

Notes to the Financial Statements - continued
for the year ended 31 December 2017

15. CALLED UP SHARE CAPITAL


Allotted and issued:
Number: Class: Nominal 2017 2016
value: £    £   
13,143 Ordinary £1 13,143 13,143

16. RESERVES
Retained Share
earnings premium Totals
£    £    £   

At 1 January 2017 (851,914 ) 214,712 (637,202 )
Deficit for the year (369,247 ) (369,247 )
At 31 December 2017 (1,221,161 ) 214,712 (1,006,449 )

17. PENSION COMMITMENTS

The company operates a contributory pension scheme. It is a defined contribution scheme and
contributions are charged in the profit and loss account as they accrue. The charge for the period
was £37,231 (2016: £37,780).

18. ULTIMATE PARENT COMPANY

Formpipe Software AB (incorporated in Sweden ) is regarded by the director as being the
company's ultimate parent company.

19. ULTIMATE CONTROLLING PARTY

The controlling party and the ultimate controlling party are not known.